STOCK TITAN

OPKO Health, Inc. - $OPK STOCK NEWS

Welcome to our dedicated page for OPKO Health news (Ticker: $OPK), a resource for investors and traders seeking the latest updates and insights on OPKO Health stock.

OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare company focused on establishing leading positions in large, rapidly growing markets. OPKO operates through two main segments: Diagnostics and Pharmaceuticals.

OPKO's Diagnostics segment includes BioReference Laboratories, the nation's third largest clinical laboratory. BioReference offers a comprehensive range of diagnostic services and features a core genetic testing business supported by a skilled 400-person sales and marketing team. Notable products include the 4Kscore® test for prostate cancer and the Claros® 1 in-office immunoassay platform.

The Pharmaceutical segment of OPKO showcases a diverse portfolio of products. Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency, was launched in November 2016. Other significant pharmaceutical developments include Varubitm for chemotherapy-induced nausea and vomiting, OPK88004 for type 2 diabetes and obesity, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia, both of which are in Phase 2 clinical trials.

OPKO has recently made headlines with strategic collaborations and technological advancements. BioReference Health, a subsidiary of OPKO, has entered a strategic alliance with SOPHiA GENETICS to incorporate MSK-ACCESS® liquid biopsy technology. This partnership aims to enhance BioReference's genomic analysis capabilities and offer state-of-the-art cancer testing across the U.S. Another collaboration with Prognos Health aims to merge genomic data with real-world data, facilitating precision medicine and improving patient outcomes.

Financially, OPKO continues to exhibit a strong performance with ongoing projects and strategic acquisitions. The acquisition of select assets from BioReference Health by Labcorp is set to expand OPKO's reach and capabilities, strengthening its market presence.

Headquartered in Miami, Florida, OPKO Health is committed to improving healthcare through innovation, scientific expertise, and strategic partnerships. For more detailed information about their products, services, and latest news, visit www.opko.com.

Rhea-AI Summary

OPKO Health (Nasdaq: OPK) will participate in the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York City. The management team will engage in one-on-one meetings with investors and join a fireside discussion on June 6th at 10:30 a.m. Eastern time. The discussion will be webcast live and available for replay on the company’s investor relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
-
Rhea-AI Summary

OPKO Health, Inc. (NASDAQ: OPK) reported first quarter 2024 business highlights and financial results. Highlights include an agreement with Labcorp to sell select assets of BioReference Health for $237.5 million, as well as FDA clearance for MDX2001, a tetraspecific antibody for solid tumor cancers. The global launch of NGENLA® by Pfizer is ongoing, with OPKO entitled to profit sharing and potential milestone payments. Financially, revenue declined to $173.7 million from $237.6 million in 2023, resulting in an operating loss of $71.5 million for Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Summary

OPKO Health, Inc. (NASDAQ: OPK) will release its financial results for the first quarter of 2024 on May 7, 2024. The company's senior management will discuss the results and provide financial guidance during a conference call and webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Labcorp (LH) to acquire select assets of BioReference Health from OPKO Health (OPK) to enhance laboratory services network and expand access to clinical laboratory services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Summary
ModeX Therapeutics, an OPKO Health company, releases positive results from a Phase 1 clinical study of SAR441236, a trispecific broadly neutralizing antibody against HIV, showing promising safety and pharmacokinetic data. The study demonstrated a similar half-life to standard monoclonal antibodies, minimal anti-drug antibodies, and consistent pharmacokinetics across all dosing regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
-
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) reported business highlights and financial results for the fourth quarter and full year 2023. Key highlights include advancements in ModeX's pipeline, global approvals for NGENLA, and BioReference Health's REACH program. Financially, revenue from products increased, while operating losses widened. The company also completed a significant convertible notes offering post-quarter-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
Rhea-AI Summary
OPKO Health, Inc. (OPK) is set to announce its operating and financial results for the three and 12 months ending December 31, 2023. The company's senior management will provide a business update and discuss financial guidance during a conference call on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences earnings
-
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the closing of a private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029, as well as a concurrent private placement of approximately $71.1 million aggregate principal amount of Convertible Senior Notes due 2029 to Frost Gamma Investments Trust, affiliated with the Company's Chairman and Chief Executive Officer. The Company received estimated net proceeds of approximately $221.4 million from the offering and used approximately $50.0 million of the net proceeds to repurchase shares of common stock from purchasers of Notes in privately negotiated transactions. Additionally, the Company repurchased for cash approximately $144.4 million aggregate principal amount of the Company’s outstanding 4.50% Convertible Senior Notes due 2025. The Notes and any shares of the common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act of 1933, as amended.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
-
Rhea-AI Summary
OPKO Health, Inc. (OPK) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, hosting one-on-one meetings with investors and presenting on January 10th. The presentation will be webcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
conferences
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029. The Notes will bear interest at a rate of 3.75% per annum, payable semiannually, and will mature on January 15, 2029. The Company also entered into separate, privately negotiated transactions to repurchase approximately $144.4 million aggregate principal amount of its outstanding 4.50% Convertible Senior Notes due 2025. The net proceeds from the offering will be approximately $192.5 million, with approximately $50.0 million to be used for repurchasing shares of common stock from purchasers of Notes in privately negotiated transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags

FAQ

What does OPKO Health Inc. specialize in?

OPKO Health Inc. specializes in diagnostics and pharmaceuticals, focusing on genetic testing and treatments for chronic diseases.

What are the main products offered by OPKO Health?

Key products include the 4Kscore® prostate cancer test, Rayaldee for secondary hyperparathyroidism, and Varubitm for chemotherapy-induced nausea.

What recent collaborations has OPKO Health announced?

OPKO Health's BioReference Health has partnered with SOPHiA GENETICS for genomic analysis and Prognos Health for real-world data integration.

Where is OPKO Health headquartered?

OPKO Health is headquartered in Miami, Florida.

What is the significance of the 4Kscore® test?

The 4Kscore® test is a blood test that helps assess the risk of aggressive prostate cancer, aiding in early detection and treatment planning.

How does BioReference Laboratories fit into OPKO Health's operations?

BioReference Laboratories is a key component of OPKO's diagnostics segment, offering comprehensive clinical and genetic testing services.

What is Rayaldee used for?

Rayaldee is used to treat secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease and vitamin D insufficiency.

What impact will the Labcorp acquisition have on OPKO Health?

The acquisition will expand OPKO's capabilities and market reach, enhancing its diagnostic services and overall market presence.

What are the future goals of OPKO Health?

OPKO aims to establish industry-leading positions in rapidly growing markets by leveraging its innovative technologies and strategic partnerships.

How can investors learn more about OPKO Health's performance?

Investors can visit OPKO's official website at www.opko.com for detailed information on financial performance, product updates, and strategic initiatives.

OPKO Health, Inc.

Nasdaq:OPK

OPK Rankings

OPK Stock Data

878.21M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIAMI